Published in Radiology on November 01, 2000
Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nat Med (2010) 3.62
Response criteria for glioma. Nat Clin Pract Oncol (2008) 2.69
Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys (2011) 2.18
Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology (2009) 2.15
End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol (2009) 2.13
Clinical impact of (11)C-methionine PET on expected management of patients with brain neoplasm. Eur J Nucl Med Mol Imaging (2009) 1.50
Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol (2011) 1.42
Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol (2011) 1.40
Computer-Extracted Texture Features to Distinguish Cerebral Radionecrosis from Recurrent Brain Tumors on Multiparametric MRI: A Feasibility Study. AJNR Am J Neuroradiol (2016) 1.39
Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology (2011) 1.38
New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol (2009) 1.36
Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol (2016) 1.32
Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. Neuro Oncol (2013) 1.30
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol (2014) 1.26
Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery. Neuro Oncol (2013) 1.18
Non-thermal irreversible electroporation (N-TIRE) and adjuvant fractionated radiotherapeutic multimodal therapy for intracranial malignant glioma in a canine patient. Technol Cancer Res Treat (2011) 1.16
Imaging in neurooncology. NeuroRx (2005) 1.14
O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging (2005) 1.14
Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro Oncol (2011) 1.13
Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastoma. J Magn Reson Imaging (2011) 1.11
Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion. Neuro Oncol (2011) 1.08
Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys (2009) 1.06
Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol. Neuro Oncol (2010) 1.01
Metabolic alterations: a biomarker for radiation-induced normal brain injury-an MR spectroscopy study. J Magn Reson Imaging (2009) 1.00
Automated brain tumor segmentation using spatial accuracy-weighted hidden Markov Random Field. Comput Med Imaging Graph (2009) 1.00
From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? Neuro Oncol (2015) 0.99
Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology (2009) 0.99
Radiation induced temporal lobe necrosis in patients with nasopharyngeal carcinoma: a review of new avenues in its management. Radiat Oncol (2011) 0.98
Brain irradiation: effects on normal brain parenchyma and radiation injury. Neuroimaging Clin N Am (2009) 0.96
Accurate differentiation of recurrent gliomas from radiation injury by kinetic analysis of α-11C-methyl-L-tryptophan PET. J Nucl Med (2012) 0.95
Growth dynamics of untreated glioblastomas in vivo. Neuro Oncol (2015) 0.95
Assessment of MRI parameters as imaging biomarkers for radiation necrosis in the rat brain. Int J Radiat Oncol Biol Phys (2012) 0.93
Dynamic Glucose-Enhanced (DGE) MRI: Translation to Human Scanning and First Results in Glioma Patients. Tomography (2015) 0.93
Quantitative multiparametric MRI assessment of glioma response to radiotherapy in a rat model. Neuro Oncol (2013) 0.93
Pathophysiology, diagnosis, and treatment of radiation necrosis in the brain. Neurol Med Chir (Tokyo) (2014) 0.93
Pros and cons of current brain tumor imaging. Neuro Oncol (2014) 0.92
Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer (2007) 0.92
Toward distinguishing recurrent tumor from radiation necrosis: DWI and MTC in a Gamma Knife--irradiated mouse glioma model. Int J Radiat Oncol Biol Phys (2014) 0.91
Impact of imaging measurements on response assessment in glioblastoma clinical trials. Neuro Oncol (2014) 0.90
Serial O-(2-[(18)F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging (2006) 0.90
Development of a novel animal model to differentiate radiation necrosis from tumor recurrence. J Neurooncol (2012) 0.90
MR imaging of late radiation therapy- and chemotherapy-induced injury: a pictorial essay. Eur Radiol (2009) 0.89
Advanced MR imaging of gliomas: an update. Biomed Res Int (2013) 0.88
Perfusion MRI: the five most frequently asked clinical questions. AJR Am J Roentgenol (2013) 0.88
Role of bevacizumab therapy in the management of glioblastoma. Cancer Manag Res (2010) 0.84
Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges. Onco Targets Ther (2013) 0.84
Temporal lobe necrosis: a dwindling entity in a patient with nasopharyngeal cancer after radiation therapy. Head Neck Oncol (2011) 0.84
Radiation necrosis of the pons after radiotherapy for nasopharyngeal carcinoma: diagnosis and treatment. J Radiol Case Rep (2012) 0.84
Texture Descriptors to distinguish Radiation Necrosis from Recurrent Brain Tumors on multi-parametric MRI. Proc SPIE Int Soc Opt Eng (2014) 0.84
The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping. Biomed Res Int (2015) 0.83
Perilesional edema in radiation necrosis reflects axonal degeneration. Radiat Oncol (2015) 0.83
Comparison of radiological and clinical features of temporal lobe necrosis in nasopharyngeal carcinoma patients treated with 2D radiotherapy or intensity-modulated radiotherapy. Br J Cancer (2014) 0.82
Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients. Vet Radiol Ultrasound (2013) 0.82
A Gamma-Knife-Enabled Mouse Model of Cerebral Single-Hemisphere Delayed Radiation Necrosis. PLoS One (2015) 0.82
A Radiation-Induced Hippocampal Vascular Injury Surrogate Marker Predicts Late Neurocognitive Dysfunction. Int J Radiat Oncol Biol Phys (2015) 0.81
The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. Cancer Manag Res (2014) 0.81
Post-treatment imaging of high-grade gliomas. Indian J Radiol Imaging (2015) 0.81
Identification of early and distinct glioblastoma response patterns treated by boron neutron capture therapy not predicted by standard radiographic assessment using functional diffusion map. Radiat Oncol (2013) 0.80
O2 -sensitive MRI distinguishes brain tumor versus radiation necrosis in murine models. Magn Reson Med (2015) 0.80
Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging. J Nucl Med (2015) 0.80
Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging. PLoS One (2013) 0.79
CT-based quantitative SPECT for the radionuclide ²⁰¹Tl: experimental validation and a standardized uptake value for brain tumour patients. Cancer Imaging (2012) 0.79
Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? J Neurooncol (2015) 0.79
Pseudoprogression after high-dose busulfan-thiotepa with autologous stem cell transplantation and radiation therapy in children with brain tumors: Impact on survival. Neuro Oncol (2012) 0.78
Dynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastoma. PLoS One (2014) 0.78
Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression? Future Oncol (2014) 0.78
Specificity of vascular endothelial growth factor treatment for radiation necrosis. Radiother Oncol (2015) 0.77
Role of optical spectroscopic methods in neuro-oncological sciences. J Lasers Med Sci (2015) 0.77
Pseudo progression identification of glioblastoma with dictionary learning. Comput Biol Med (2016) 0.77
Clinical observation of peripheral nerve injury in 2 patients with cancer after radiotherapy. Contemp Oncol (Pozn) (2013) 0.77
Thallium-201 SPECT: the optimal prediction of response in glioma therapy. Eur J Nucl Med Mol Imaging (2005) 0.77
Apparent diffusion coefficient parametric response mapping MRI for follow-up of glioblastoma. Eur Radiol (2015) 0.76
Amino Acid PET - An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence? Front Neurol (2016) 0.76
The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. Neuroimage Clin (2016) 0.76
Added value of amide proton transfer imaging to conventional and perfusion MR imaging for evaluating the treatment response of newly diagnosed glioblastoma. Eur Radiol (2016) 0.76
MRI and thallium-201 SPECT in the prediction of survival in glioma. Neuroradiology (2011) 0.76
Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial. BMC Med Imaging (2017) 0.75
Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications. Br J Radiol (2011) 0.75
Radiation-induced secondary narcolepsy. Ann Indian Acad Neurol (2015) 0.75
Differentiation between recurrent gliomas and radiation necrosis using arterial spin labeling perfusion imaging. Exp Ther Med (2016) 0.75
Delayed cerebral radiation necrosis following treatment for a plasmacytoma of the skull. Surg Neurol Int (2010) 0.75
Molecular Imaging Using Endogenous Cellular Proteins. Bo Pu Xue Za Zhi (2013) 0.75
Role of neuroimaging in multidisciplinary approach towards Non-Alzheimer's dementia. Insights Imaging (2015) 0.75
Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma. Neuroradiology (2017) 0.75
Neurologic Applications of PET/MR Imaging. Magn Reson Imaging Clin N Am (2017) 0.75
Radiation necrosis masquerading as late tumor recurrence: 14 years after combined fractionated stereotactic radiosurgery and conventional radiation therapy. Radiol Case Rep (2015) 0.75
Neuroimaging findings of the post-treatment effects of radiation and chemotherapy of malignant primary glial neoplasms. Neuroradiol J (2013) 0.75
Differential diagnosis of a vanishing brain space occupying lesion in a child. World J Clin Cases (2015) 0.75
Detection of residual metastatic tumor in the brain following Gamma Knife radiosurgery using a single or a series of magnetic resonance imaging scans: An autopsy study. Oncol Lett (2017) 0.75
Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy. Neuro Oncol (2017) 0.75
Can anti-vascular endothelial growth factor antibody reverse radiation necrosis? A preclinical investigation. J Neurooncol (2017) 0.75
[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme]. Wien Med Wochenschr (2011) 0.75
[Molecular imaging in neurological diseases]. Radiologe (2016) 0.75
Stereotactic ablative radiation therapy for brain metastases with volumetric modulated arc therapy and flattening filter free delivery: feasibility and early clinical results. Radiol Med (2017) 0.75
Magnetic resonance imaging patterns of treatment-related toxicity in the pediatric brain: an update and review of the literature. Pediatr Radiol (2016) 0.75
Asymptomatic cystic changes in the brain of children after cranial irradiation: frequency, latency, and relationship to age. Neuroradiology (2007) 0.75
Added value of diffusion weighted imaging in pediatric central nervous system embryonal tumors surveillance. Oncotarget (2017) 0.75
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol (1999) 8.69
Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet (2000) 5.28
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer (2000) 4.96
PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev (2001) 4.53
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A (1990) 4.42
Lumbar puncture needn't be a headache. BMJ (1997) 3.65
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol (1999) 3.30
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 2.81
An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg (2000) 2.50
Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg (1977) 2.39
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol (2000) 2.22
Primary radiotherapy in the treatment of stage I and II oral tongue cancers: importance of the proportion of therapy delivered with interstitial therapy. Int J Radiat Oncol Biol Phys (1990) 2.07
Gamma-radiation sensitivity and risk of glioma. J Natl Cancer Inst (2001) 2.06
Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol (1996) 2.04
Successful therapy for trilateral retinoblastoma. Am J Ophthalmol (1992) 2.03
Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem (1980) 2.01
The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells. Nat Med (2000) 1.92
Diagnostic discrepancies and their clinical impact in a neuropathology referral practice. Cancer (1997) 1.86
Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys (1993) 1.85
Germline p53 gene mutations in subsets of glioma patients. J Natl Cancer Inst (1994) 1.81
Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery (1999) 1.79
Primary extradural meningiomas: a report on nine cases and review of the literature from the era of computerized tomography scanning. J Neurosurg (2000) 1.75
Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC Cooperative Randomized Study. Int J Radiat Oncol Biol Phys (1988) 1.71
Intracranial injection of human meningioma cells in athymic mice: an orthotopic model for meningioma growth. J Neurosurg (2000) 1.70
Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol (2011) 1.70
Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol (2000) 1.66
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys (2002) 1.61
Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J Clin Oncol (1991) 1.60
Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. Int J Radiat Oncol Biol Phys (1991) 1.59
Intracranial metastatic melanoma: correlation between MR imaging characteristics and melanin content. AJR Am J Roentgenol (1995) 1.58
Response and progression in recurrent malignant glioma. Neuro Oncol (1999) 1.57
Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol (2001) 1.53
Hiccups and human purpose. Nature (1990) 1.50
Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery (1987) 1.49
Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol (1996) 1.48
Pineal region tumors in children. J Neurosurg (1988) 1.47
Does chemotherapy benefit the patient with a central nervous system glioma? Oncology (Williston Park) (1987) 1.47
Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol (1997) 1.47
Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiother Oncol (1991) 1.47
Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology (1998) 1.46
The treatment of brain stem and thalamic gliomas with 78 Gy of hyperfractionated radiation therapy. Int J Radiat Oncol Biol Phys (1995) 1.45
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys (1995) 1.41
Fast neutron radiotherapy for locally advanced prostate cancer: results of an RTOG randomized study. Int J Radiat Oncol Biol Phys (1985) 1.38
Neuropathies in AIDS. Br J Hosp Med (1991) 1.38
Fibroblast growth factor receptor-1 alpha-exon exclusion and polypyrimidine tract-binding protein in glioblastoma multiforme tumors. Cancer Res (2000) 1.37
Progressive multifocal leukoencephalopathy: clinical and radiographic features. Ann Neurol (1985) 1.35
Sucrose and inulin space measurements of cerebral cortex in four mammalian species. Am J Physiol (1970) 1.32
Lymphoma of the head and neck. Radiol Clin North Am (1990) 1.31
Craniofacial osteosarcomas: plain film, CT, and MR findings in 46 cases. AJR Am J Roentgenol (1988) 1.31
Cell kinetic studies of in situ human brain tumors with bromodeoxyuridine. Cytometry (1985) 1.30
Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology (1988) 1.28
Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res (2000) 1.27
Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys (1990) 1.27
Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res (1996) 1.26
Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg (1986) 1.26
The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol (1998) 1.26
Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol (1998) 1.25
External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys (1997) 1.25
Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys (1993) 1.25
Loss of heterozygosity for 10q loci in human gliomas. Genes Chromosomes Cancer (1992) 1.24
Intraventricular septations complicating neonatal meningitis. J Neurosurg (1973) 1.21
Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res (1996) 1.21
Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo. Am J Pathol (2000) 1.21
Factors influencing the survival of rat brain tumor cells after in vitro treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res (1975) 1.21
Sarcoma metastatic to the brain: results of surgical treatment. Neurosurgery (1994) 1.19
Utility of postmortem magnetic resonance imaging in clinical neuropathology. Arch Pathol Lab Med (1994) 1.19
Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med (1998) 1.18
Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. AJR Am J Roentgenol (1989) 1.17
Non-Hodgkin's lymphoma involving the gynecologic tract: a review of 88 cases. Adv Anat Pathol (2001) 1.17
Normal and variant anatomy of the dural venous sinuses. Semin Ultrasound CT MR (1994) 1.15
Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation. Oncogene (1991) 1.15
Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential. Amino Acids (2007) 1.14
Cerebrospinal fluid production by the choroid plexus and brain. Science (1971) 1.14
Activity of pp60c-src in 60 different cell lines derived from human tumors. Cancer Biochem Biophys (1994) 1.13
Age-related chemosensitivity of stem cells from human malignant brain tumours. Lancet (1982) 1.13
Collateral circulation in cerebrovascular disease in childhood via rete mirabile and perforating branches of anterior choroidal and posterior cerebral arteries. Radiology (1965) 1.13
Diagnostic potential of laser-induced autofluorescence emission in brain tissue. J Korean Med Sci (1997) 1.13
Chondrosarcoma of the spine: 1954 to 1997. J Neurosurg (1999) 1.12
Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res (1996) 1.12
MR imaging of papillary tumor of the pineal region. AJNR Am J Neuroradiol (2007) 1.11
Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. J Neurosurg (1991) 1.11
Pseudospread of the atlas: false sign of Jefferson fracture in young children. AJR Am J Roentgenol (1983) 1.10
Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep (1980) 1.09
Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis (1996) 1.09
Craniospinal dissemination of central neurocytoma. Report of two cases. J Neurosurg (1997) 1.08
Mixed neutron/photon irradiation of unresectable squamous cell carcinomas of the head and neck: the final report of a randomized cooperative trial. Int J Radiat Oncol Biol Phys (1989) 1.08
Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp Metastasis (1996) 1.08
Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst (1997) 1.07
Angiographic manifestations in cerebral inflammatory disease. Radiology (1971) 1.07
Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys (1979) 1.06
Evaluation of malignant glioma patients during the postirradiation period. J Neurosurg (1979) 1.06
Stages IE and IIE non-Hodgkin's lymphomas of the stomach. Comparison of treatment modalities. Cancer (1984) 1.06
Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. J Neurosurg (1987) 1.05
Eight years experience with neutron radiotherapy in the treatment of stages C and D prostate cancer: updated results of the RTOG 7704 randomized clinical trial. Prostate (1987) 1.04